Article
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Cancer research - 15 Mar 2001
Geisler S, Lønning P E, Aas T, Johnsen H, Fluge O, Haugen D F, Lillehaug J R, Akslen L A, Børresen-Dale A L
Abstract excerpt
TP53 status [mutations, immunostaining, and loss of heterozygosity (LOH)], expression of c-erbB-2, bcl-2, and histological grading were correlated to the response to doxorubicin monotherapy (14 mg/m2) administered weekly to 90 patients with locally advanced breast cancer. Mutations in the TP53 gene, in particular those affecting or disrupting the loop domains L2 or L3 of the p53 protein, were associated with lack...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.